New England Journal of Medicine· 2019Q1

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho et al.

2,846citations
Q1SCImago
2019year

Short summary

First-line osimertinib significantly improved overall survival by 6.8 months (38.6 vs. 31.8 months) in patients with untreated, EGFR-mutated advanced non-small-cell lung cancer (NSCLC) compared to other EGFR-TKIs.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine